How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-after-at-least-two-prior-therapies.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Allr3	allr3	Pfizer	The pharmacological class of ALLR3 is not specified.	The molecular target of ALLR3 is not specified.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 1 drug in Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies:

Cite this brief

Drug Landscape (2026). Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-after-at-least-two-prior-therapies. Accessed 2026-06-10.

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing